Biothera and World Medicine Partners to Commercialize BAT2206 (Biosimilar: Ustekinumab) in Turkey
Shots:
- Bio-Thera & World Medicine entered into an exclusive license & commercialization agreement for BAT2206, a biosimilar to Janssen’s Stelara (ustekinumab), leveraging World Medicine’s marketing expertise & distribution network in Turkey
- As per the terms, World Medicine will hold market approval of BAT2206 in Turkey as well as its registration, imports, promotion & marketing, while Bio-Thera will handle the commercial supply & manufacturing in its Guangzhou facilities
- In addition, Bio-Thera has submitted MAA for BAT2206 to China's NMPA, EMA & the US FDA
Ref: Biothera | Image: Biothera & World Medicine
Related News:- Candid Therapeutics Partners with EpimAb Biotherapeutics to Develop T-Cell Engagers for Autoimmune Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
